Updated:
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals develops therapies for neurological disorders and rare diseases including Parkinson's disease psychosis and Rett syndrome.
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals, headquartered in San Diego, California, focuses on neurology and rare diseases with an emphasis on conditions lacking effective therapies. Its history includes developing NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions in Parkinson's disease psychosis (approved in 2016 per the firm), and DAYBUE, the first therapy approved for Rett syndrome (per the firm, 2023). The company targets three therapeutic areas: Parkinson's disease psychosis (PDP), affecting about half of Parkinson's patients over the disease course; Rett syndrome, a rare genetic neurological disorder; and Alzheimer's disease psychosis, which studies suggest occurs in approximately 30 percent of Alzheimer's patients. Acadia's pipeline and commercial portfolio rely on internal R&D and external partnerships, with a stated focus on bringing novel therapies to patients with few alternatives. Geographically, the firm serves patients in North America and Europe, with offices in Princeton, Oakville, Basel, Zug, and Amsterdam. Acadia's team operates across these offices, with leadership dedicated to neurological and rare disease innovation. A recent example of activity includes a series of news updates, such as a general release on May 6, 2026 (per the firm), though specific operational events within the last 24 months remain limited in public detail. The firm also maintains a corporate responsibility program emphasizing ethics and sustainability. A structural differentiator is Acadia's focus on underserved, non-motor symptoms of major neurological diseases—areas often deprioritized by larger pharmaceutical companies. Its regulatory success with two first-in-class drug approvals demonstrates a targeted development model aimed at niche but significant patient populations.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
12830 El Camino Real, Suite 400, San Diego, CA 92130, United States
Additional offices
Princeton, New Jersey, United States · Oakville, Ontario, Canada · Basel, Switzerland · Zug, Switzerland · Amsterdam, Netherlands
Sector focus
Frequently asked questions
Who runs investment decisions at Acadia Pharmaceuticals?
Acadia Pharmaceuticals is a publicly traded biopharmaceutical company, not a family office or investment firm. Investment and capital allocation decisions are made by its executive leadership and board of directors, as typical for a corporation. The firm's leadership includes a CEO and a management team focused on R&D and commercialization.
How does Acadia source its drug development pipeline?
Acadia develops therapies through internal research and development as well as external partnerships and collaborations. The firm states it actively seeks partnerships that drive therapeutic advancements for patients. Its published pipeline focuses on neurological disorders and rare diseases, with a history of advancing candidates from early research to FDA approval.
Is Acadia a family office or asset manager?
No. Acadia Pharmaceuticals is a publicly traded biopharmaceutical company (NASDAQ: ACAD), not a family office, asset manager, or investment vehicle. It operates as a drug developer and commercializer for neurological and rare disease indications.
What investment stages does Acadia typically target?
Acadia is not an investment firm; it does not target investment stages. As a pharmaceutical company, it advances drug candidates from preclinical research through clinical trials and regulatory approval.
Which sectors does Acadia explicitly avoid?
Acadia does not publicly disclose avoided sectors. Its stated focus is on neurological disorders and rare diseases with limited treatment options, including Parkinson's disease psychosis, Rett syndrome, and Alzheimer's disease psychosis.
Does Acadia maintain philanthropic structures?
Acadia has a corporate responsibility program anchored in ethics and sustainability, but does not publicly disclose a separate philanthropic foundation or charitable vehicle. The company's programs focus on patient and community support, including patient stories and partnerships detailed on its website.
Where does the underlying wealth come from for Acadia?
Acadia Pharmaceuticals is a publicly traded company, generating revenue through sales of its approved drugs (NUPLAZID and DAYBUE) and financing through equity/debt markets. Wealth is generated from commercial operations, not from any individual or family fortune.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: